NASDAQ:PBYI Puma Biotechnology Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Puma Biotechnology Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $10.41 +0.36 (+3.58 %) (As of 09/30/2020 12:11 PM ET) Add Compare Share Today's Range$10.10Now: $10.41▼$10.4250-Day Range$9.50MA: $10.07▼$11.1452-Week Range$5.50Now: $10.41▼$15.00Volume4,352 shsAverage Volume1.30 million shsMarket Capitalization$413.04 millionP/E RatioN/ADividend YieldN/ABeta1.24 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.Read More Beat the Market (BTM) Rank™ 1.9 Analyst's Opinion Consensus RatingPuma Biotechnology has received a consensus rating of Hold. The company's average rating score is 1.80, and is based on 1 buy rating, 6 hold ratings, and 3 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.78, Puma Biotechnology has a forecasted upside of 14.9% from its current price of $10.25.Amount of Analyst CoveragePuma Biotechnology has only been the subject of 2 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesPuma Biotechnology has received 507 “outperform” votes. (Add your “outperform” vote.)Underperform VotesPuma Biotechnology has received 505 “underperform” votes. (Add your “underperform” vote.)Community SentimentPuma Biotechnology has received 50.10% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Puma Biotechnology and other stocks. Vote “Outperform” if you believe PBYI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PBYI will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldPuma Biotechnology does not currently pay a dividend.Dividend GrowthPuma Biotechnology does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Puma Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $137,065.00 in company stock.Percentage Held by InsidersOnly 21.20% of the stock of Puma Biotechnology is held by insiders.Percentage Held by Institutions88.45% of the stock of Puma Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Puma Biotechnology are expected to grow in the coming year, from ($0.91) to ($0.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Puma Biotechnology is -9.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Puma Biotechnology is -9.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPuma Biotechnology has a P/B Ratio of 22.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.9Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.21 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PBYI Previous Symbol CUSIPN/A CIK1401667 Webwww.pumabiotechnology.com Phone424-248-6500Debt Debt-to-Equity Ratio4.13 Current Ratio1.68 Quick Ratio1.65Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$272.30 million Price / Sales1.52 Cash FlowN/A Price / Cash FlowN/A Book Value$0.45 per share Price / Book23.13Profitability EPS (Most Recent Fiscal Year)($1.95) Net Income$-75,600,000.00 Net Margins-17.25% Return on Equity-246.80% Return on Assets-17.40%Miscellaneous Employees272 Outstanding Shares39,677,000Market Cap$413.04 million Next Earnings Date11/4/2020 (Estimated) OptionableOptionable $10.41 +0.36 (+3.58 %) (As of 09/30/2020 12:11 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive PBYI News and Ratings via Email Sign-up to receive the latest news and ratings for PBYI and its competitors with MarketBeat's FREE daily newsletter. Puma Biotechnology (NASDAQ:PBYI) Frequently Asked Questions How has Puma Biotechnology's stock price been impacted by Coronavirus (COVID-19)? Puma Biotechnology's stock was trading at $9.27 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PBYI shares have increased by 11.8% and is now trading at $10.36. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Puma Biotechnology? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Puma Biotechnology in the last year. There are currently 3 sell ratings, 6 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Puma Biotechnology. When is Puma Biotechnology's next earnings date? Puma Biotechnology is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for Puma Biotechnology. How were Puma Biotechnology's earnings last quarter? Puma Biotechnology Inc (NASDAQ:PBYI) posted its quarterly earnings data on Thursday, August, 6th. The biopharmaceutical company reported $0.08 EPS for the quarter, topping the consensus estimate of ($0.26) by $0.34. The biopharmaceutical company earned $70.60 million during the quarter, compared to analyst estimates of $58.21 million. Puma Biotechnology had a negative return on equity of 246.80% and a negative net margin of 17.25%. Puma Biotechnology's revenue was up 31.0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.57) EPS. View Puma Biotechnology's earnings history. What price target have analysts set for PBYI? 10 brokers have issued 1-year price objectives for Puma Biotechnology's shares. Their forecasts range from $6.00 to $17.00. On average, they expect Puma Biotechnology's share price to reach $11.78 in the next year. This suggests a possible upside of 13.7% from the stock's current price. View analysts' price targets for Puma Biotechnology. Who are some of Puma Biotechnology's key competitors? Some companies that are related to Puma Biotechnology include Cytokinetics (CYTK), Amarin (AMRN), Ligand Pharmaceuticals (LGND), Ironwood Pharmaceuticals (IRWD), ZEALAND PHARMA/S (ZEAL), Generation Bio (GBIO), ALX Oncology (ALXO), Myovant Sciences (MYOV), Intercept Pharmaceuticals (ICPT), Dicerna Pharmaceuticals (DRNA), MacroGenics (MGNX), Heron Therapeutics (HRTX), Passage Bio (ZNTL), Trillium Therapeutics (TRIL) and Mersana Therapeutics (MRSN). View all competitors. What other stocks do shareholders of Puma Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Puma Biotechnology investors own include Medivation (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Continental (UAL), Kite Pharma (KITE), Array Biopharma (ARRY), Freeport-McMoRan (FCX) and Celgene (CELG). Who are Puma Biotechnology's key executives? Puma Biotechnology's management team includes the following people: Mr. Alan H. Auerbach, Founder, Chairman, Pres, CEO & Sec. (Age 49)Dr. Richard P. Bryce, Chief Medical & Scientific Officer (Age 62)Mr. Steven Lo, Chief Commercial Officer (Age 52)Mr. Charles R. Eyler, Sr. VP of Fin. & Admin. and Treasurer (Age 71)Mr. Maximo F. Nougues, CFO & Principal Accounting Officer (Age 50) What is Puma Biotechnology's stock symbol? Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI." How do I buy shares of Puma Biotechnology? Shares of PBYI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Puma Biotechnology's stock price today? One share of PBYI stock can currently be purchased for approximately $10.36. How big of a company is Puma Biotechnology? Puma Biotechnology has a market capitalization of $411.05 million and generates $272.30 million in revenue each year. The biopharmaceutical company earns $-75,600,000.00 in net income (profit) each year or ($1.95) on an earnings per share basis. Puma Biotechnology employs 272 workers across the globe. What is Puma Biotechnology's official website? The official website for Puma Biotechnology is www.pumabiotechnology.com. How can I contact Puma Biotechnology? Puma Biotechnology's mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The biopharmaceutical company can be reached via phone at 424-248-6500 or via email at [email protected] This page was last updated on 9/30/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
